Skip to content

R&D at other companies

Eli Lilly logo
Eli LillyLLY
$3.51B+28.4%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$126.64M+13.6%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$75.37M+19.6%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$33.53M-8.0%
CG Oncology logo
CG OncologyCGON
$43.73M+59.2%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$68.57M-5.4%

Other financials

Income statement

See full
Operating income-$50.5M-39.8%
Net income-$52.8M-42.8%
EPS (diluted)-$0.97-12.8%

Balance sheet

See full
Cash & equivalents$145.2M+781%
Total debt$137.9M+30.7%
Total equity$53.5M-38.2%
Total assets$410.2M+88.0%

Cash flow

See full
Operating cash flow-$55.1M-53.6%
CapEx$249.0K+315%
Free cash flow-$55.3M-54.0%

Valuation

See full
Market cap$4.28B+1,370%
Enterprise value$4.27B+1,086%

Returns & leverage

See full
Return on equity-275.2%-990pp
Debt / equity2.6×+1.4×
Current ratio12.3×+5.7×

Where this comes from

Reported directly by Celcuity in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Celcuity’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Celcuity's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Celcuity's R&D?
Celcuity (CELC) reported R&D of $33.06M in Q1 2026.
How has Celcuity's R&D changed year-over-year?
Celcuity's R&D increased by 11.1% year-over-year, from $29.76M to $33.06M.
What is the long-term trend for Celcuity's R&D?
Over 4 years (2021 to 2025), Celcuity's R&D has grown at a 53.4% compound annual growth rate (CAGR), from $25.76M to $142.53M.
What does R&D mean?
Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.